Form 8-K - Current report:
SEC Accession No. 0001193125-23-291257
Filing Date
2023-12-08
Accepted
2023-12-08 08:45:59
Documents
18
Period of Report
2023-12-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d577229d8k.htm   iXBRL 8-K 39353
2 EX-3.1 d577229dex31.htm EX-3.1 77119
3 EX-10.1 d577229dex101.htm EX-10.1 309444
4 EX-10.2 d577229dex102.htm EX-10.2 137218
5 EX-99.1 d577229dex991.htm EX-99.1 12143
9 GRAPHIC g577229g1208035446685.jpg GRAPHIC 3643
10 GRAPHIC g577229g1208042156924.jpg GRAPHIC 3643
  Complete submission text file 0001193125-23-291257.txt   851494

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA syre-20231207.xsd EX-101.SCH 2877
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE syre-20231207_lab.xml EX-101.LAB 19502
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syre-20231207_pre.xml EX-101.PRE 12174
12 EXTRACTED XBRL INSTANCE DOCUMENT d577229d8k_htm.xml XML 3723
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231474016
SIC: 2834 Pharmaceutical Preparations